These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 14639057)

  • 21. Association between multidrug resistance 1 (MDR1) gene polymorphisms and therapeutic response to bromperidol in schizophrenic patients: a preliminary study.
    Yasui-Furukori N; Saito M; Nakagami T; Kaneda A; Tateishi T; Kaneko S
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Mar; 30(2):286-91. PubMed ID: 16386826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of SSI with APCI as an interface of HPLC-mass spectrometry for analysis of a drug and its metabolites.
    Arinobu T; Hattori H; Seno H; Ishii A; Suzuki O
    J Am Soc Mass Spectrom; 2002 Mar; 13(3):204-8. PubMed ID: 11908800
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Determination of bromperidol in serum by automated column-switching high-performance liquid chromatography.
    Hikida K; Inoue Y; Miyazaki T; Kojima N; Ohkura Y
    J Chromatogr; 1989 Oct; 495():227-34. PubMed ID: 2613807
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neuroleptic drugs in breast-milk: a study of pharmacokinetics and of possible adverse effects in breast-fed infants.
    Yoshida K; Smith B; Craggs M; Kumar R
    Psychol Med; 1998 Jan; 28(1):81-91. PubMed ID: 9483685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CYP3A is responsible for N-dealkylation of haloperidol and bromperidol and oxidation of their reduced forms by human liver microsomes.
    Tateishi T; Watanabe M; Kumai T; Tanaka M; Moriya H; Yamaguchi S; Satoh T; Kobayashi S
    Life Sci; 2000 Nov; 67(24):2913-20. PubMed ID: 11133003
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma concentrations of antipsychotic drugs in psychiatric inpatients.
    Tokunaga H; Kudo K; Imamura T; Jitsufuchi N; Ohtsuka Y; Ikeda N
    Nihon Hoigaku Zasshi; 1997 Dec; 51(6):417-22. PubMed ID: 9545754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical efficacy, extrapyramidal symptoms and serum levels: influence of administration schedules and concomitant drugs on serum bromperidol concentrations.
    Fujii Y; Tateyama M; Kamisada M; Tanoue A; Takamiya M; Nakajima S; Itoh H
    Folia Psychiatr Neurol Jpn; 1984; 38(2):121-36. PubMed ID: 6152433
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open study with bromperidol in hospitalized chronic schizophrenic patients.
    Hermans W
    Acta Psychiatr Belg; 1978; 78(1):89-95. PubMed ID: 347883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analytical methods for the determination of bromperidol in plasma.
    Van den Eeckhout E; Belpaire F
    Acta Psychiatr Belg; 1978; 78(1):64-8. PubMed ID: 645408
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of itraconazole on the steady-state plasma concentrations of bromperidol and reduced bromperidol in schizophrenic patients.
    Furukori H; Kondo T; Yasui N; Otani K; Tokinaga N; Nagashima U; Kaneko S; Inoue Y
    Psychopharmacology (Berl); 1999 Jul; 145(2):189-92. PubMed ID: 10463320
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Conversion of bromperidol to reduced bromperidol in human liver.
    Someya T; Inaba T; Tyndale RF; Tang SW; Takahashi S
    Neuropsychopharmacology; 1991 Nov; 5(3):177-82. PubMed ID: 1755933
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Involvement of CYP3A4 in the metabolism of bromperidol in vitro.
    Sato S; Someya T; Shioiri O; Koitabashi T; Inoue Y
    Pharmacol Toxicol; 2000 Mar; 86(3):145-8. PubMed ID: 10752674
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liquid chromatographic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine.
    Arinobu T; Hattori H; Iwai M; Ishii A; Kumazawa T; Suzuki O; Seno H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Aug; 776(1):107-13. PubMed ID: 12127331
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.
    Woggon B
    Acta Psychiatr Belg; 1978; 78(1):155-72. PubMed ID: 347878
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Butyrophenone derivatives].
    Hirokane G; Shimoda K
    Nihon Rinsho; 2004 Dec; 62 Suppl 12():377-9. PubMed ID: 15658342
    [No Abstract]   [Full Text] [Related]  

  • 36. Bromperidol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in psychoses.
    Benfield P; Ward A; Clark BG; Jue SG
    Drugs; 1988 Jun; 35(6):670-84. PubMed ID: 3048975
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic parameters of bromperidol in Korean subjects.
    Lee SY; Kim YG; Kim HG; Kim JW
    Hum Psychopharmacol; 2006 Aug; 21(6):409-12. PubMed ID: 16915578
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Solid-phase extraction and high-performance liquid chromatography for therapeutic monitoring of haloperidol levels.
    Hoffman DW; Edkins RD
    Ther Drug Monit; 1994 Oct; 16(5):504-8. PubMed ID: 7846750
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High throughput identification and quantification of 16 antipsychotics and 8 major metabolites in serum using ultra-high performance liquid chromatography-tandem mass spectrometry.
    Patteet L; Maudens KE; Sabbe B; Morrens M; De Doncker M; Neels H
    Clin Chim Acta; 2014 Feb; 429():51-8. PubMed ID: 24291056
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determination of haloperidol and its reduced metabolite in human plasma by liquid chromatography-mass spectrometry with electrospray ionization.
    Hoja H; Marquet P; Verneuil B; Lotfi H; Dupuy JL; Pénicaut B; Lachâtre G
    J Chromatogr B Biomed Sci Appl; 1997 Jan; 688(2):275-80. PubMed ID: 9061465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.